 Jennifer Barker
Concepts (172)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Addison Disease | 6 | 2012 | 40 | 1.520 |
Why?
| | Diabetes Mellitus, Type 1 | 21 | 2012 | 3254 | 1.520 |
Why?
| | Autoantibodies | 15 | 2012 | 1347 | 1.140 |
Why?
| | Autoimmune Diseases | 6 | 2011 | 381 | 0.990 |
Why?
| | Steroid 21-Hydroxylase | 4 | 2012 | 30 | 0.760 |
Why?
| | Endocrine System Diseases | 2 | 2015 | 30 | 0.730 |
Why?
| | Anorexia Nervosa | 1 | 2021 | 63 | 0.700 |
Why?
| | Metabolic Diseases | 2 | 2015 | 98 | 0.530 |
Why?
| | Celiac Disease | 4 | 2008 | 264 | 0.500 |
Why?
| | Emergencies | 1 | 2015 | 143 | 0.460 |
Why?
| | Adrenal Hyperplasia, Congenital | 1 | 2013 | 28 | 0.410 |
Why?
| | Disease Management | 1 | 2015 | 556 | 0.380 |
Why?
| | Neonatal Screening | 1 | 2013 | 151 | 0.370 |
Why?
| | Turner Syndrome | 2 | 2022 | 45 | 0.370 |
Why?
| | Histocompatibility Antigens Class I | 2 | 2009 | 170 | 0.360 |
Why?
| | Insulin Antibodies | 2 | 2009 | 102 | 0.350 |
Why?
| | HLA-D Antigens | 1 | 2008 | 34 | 0.310 |
Why?
| | HLA-DQ Antigens | 5 | 2009 | 174 | 0.290 |
Why?
| | Hypoglycemia | 1 | 2012 | 386 | 0.290 |
Why?
| | Polymorphism, Genetic | 2 | 2009 | 610 | 0.280 |
Why?
| | Insulin-Secreting Cells | 2 | 2008 | 317 | 0.280 |
Why?
| | Child | 19 | 2022 | 18400 | 0.280 |
Why?
| | Sweetening Agents | 1 | 2007 | 37 | 0.270 |
Why?
| | Preventive Medicine | 1 | 2006 | 38 | 0.260 |
Why?
| | Primary Prevention | 1 | 2007 | 172 | 0.250 |
Why?
| | Autoimmunity | 5 | 2010 | 812 | 0.240 |
Why?
| | Disease Progression | 5 | 2012 | 2371 | 0.240 |
Why?
| | Humans | 35 | 2022 | 114043 | 0.240 |
Why?
| | HLA-DR Antigens | 4 | 2009 | 219 | 0.220 |
Why?
| | Mass Screening | 3 | 2012 | 979 | 0.220 |
Why?
| | HLA-DR3 Antigen | 3 | 2010 | 79 | 0.220 |
Why?
| | Metabolic Syndrome | 1 | 2007 | 320 | 0.220 |
Why?
| | Adolescent | 13 | 2022 | 17800 | 0.220 |
Why?
| | Insulin | 3 | 2008 | 2080 | 0.210 |
Why?
| | Polymorphism, Single Nucleotide | 3 | 2011 | 1880 | 0.210 |
Why?
| | Biomarkers | 2 | 2012 | 3397 | 0.210 |
Why?
| | Parental Leave | 1 | 2022 | 17 | 0.210 |
Why?
| | Prediabetic State | 2 | 2009 | 219 | 0.200 |
Why?
| | Tetany | 1 | 2002 | 3 | 0.200 |
Why?
| | Interferon-alpha | 3 | 2009 | 185 | 0.190 |
Why?
| | Glucose | 1 | 2007 | 899 | 0.190 |
Why?
| | Monosomy | 1 | 2021 | 11 | 0.180 |
Why?
| | Genotype | 5 | 2011 | 1757 | 0.180 |
Why?
| | Sex Chromosome Aberrations | 1 | 2021 | 51 | 0.180 |
Why?
| | Disorders of Sex Development | 1 | 2021 | 34 | 0.180 |
Why?
| | Fellowships and Scholarships | 1 | 2022 | 224 | 0.170 |
Why?
| | Polyendocrinopathies, Autoimmune | 2 | 2011 | 18 | 0.170 |
Why?
| | Liver Diseases | 1 | 2022 | 254 | 0.170 |
Why?
| | Islets of Langerhans | 5 | 2009 | 728 | 0.160 |
Why?
| | Risk Factors | 6 | 2012 | 8614 | 0.160 |
Why?
| | Blood Glucose | 2 | 2009 | 1827 | 0.160 |
Why?
| | Genetic Predisposition to Disease | 5 | 2011 | 2090 | 0.150 |
Why?
| | Adrenocorticotropic Hormone | 2 | 2012 | 128 | 0.150 |
Why?
| | Glucose Tolerance Test | 3 | 2009 | 343 | 0.150 |
Why?
| | Hydrocortisone | 2 | 2012 | 267 | 0.140 |
Why?
| | HLA-DR4 Antigen | 2 | 2008 | 76 | 0.130 |
Why?
| | Female | 14 | 2022 | 59325 | 0.130 |
Why?
| | Time Factors | 4 | 2012 | 6077 | 0.130 |
Why?
| | Child, Preschool | 7 | 2011 | 9114 | 0.120 |
Why?
| | Hospitalization | 1 | 2004 | 1762 | 0.120 |
Why?
| | Predictive Value of Tests | 3 | 2012 | 1791 | 0.120 |
Why?
| | Administration, Oral | 2 | 2007 | 725 | 0.120 |
Why?
| | Male | 12 | 2021 | 55396 | 0.120 |
Why?
| | Follow-Up Studies | 3 | 2012 | 4392 | 0.120 |
Why?
| | Morbidity | 1 | 2015 | 277 | 0.120 |
Why?
| | Infant, Newborn | 4 | 2013 | 5038 | 0.110 |
Why?
| | Global Health | 1 | 2015 | 284 | 0.110 |
Why?
| | Genetic Testing | 2 | 2006 | 381 | 0.110 |
Why?
| | Proportional Hazards Models | 2 | 2007 | 1078 | 0.100 |
Why?
| | Renin | 1 | 2012 | 31 | 0.100 |
Why?
| | Haplotypes | 3 | 2011 | 448 | 0.100 |
Why?
| | HLA-B Antigens | 1 | 2011 | 56 | 0.090 |
Why?
| | Prognosis | 2 | 2012 | 3315 | 0.090 |
Why?
| | Potassium Channels | 1 | 2011 | 121 | 0.090 |
Why?
| | Gene Frequency | 2 | 2010 | 476 | 0.090 |
Why?
| | Endocrine Cells | 1 | 2010 | 6 | 0.090 |
Why?
| | Alleles | 2 | 2011 | 789 | 0.090 |
Why?
| | Models, Biological | 2 | 2008 | 1611 | 0.090 |
Why?
| | Monitoring, Immunologic | 1 | 2009 | 23 | 0.080 |
Why?
| | HLA-DQ beta-Chains | 1 | 2009 | 57 | 0.080 |
Why?
| | Graves Disease | 1 | 2009 | 34 | 0.080 |
Why?
| | HLA-DRB1 Chains | 1 | 2009 | 97 | 0.080 |
Why?
| | Microsatellite Repeats | 1 | 2009 | 137 | 0.080 |
Why?
| | Homozygote | 1 | 2009 | 187 | 0.080 |
Why?
| | Antibody Specificity | 2 | 2007 | 175 | 0.080 |
Why?
| | Fluoroimmunoassay | 1 | 2007 | 3 | 0.070 |
Why?
| | Diet, Gluten-Free | 1 | 2008 | 30 | 0.070 |
Why?
| | Histocompatibility Antigens | 1 | 2008 | 98 | 0.070 |
Why?
| | Transglutaminases | 1 | 2008 | 142 | 0.070 |
Why?
| | Polymerase Chain Reaction | 1 | 2009 | 990 | 0.070 |
Why?
| | Immunoglobulin A | 1 | 2008 | 166 | 0.070 |
Why?
| | Nutritional Physiological Phenomena | 1 | 2006 | 47 | 0.070 |
Why?
| | Adrenal Gland Diseases | 1 | 2006 | 6 | 0.070 |
Why?
| | Thyroiditis, Autoimmune | 1 | 2006 | 13 | 0.060 |
Why?
| | Thyroglobulin | 1 | 2005 | 17 | 0.060 |
Why?
| | Iodide Peroxidase | 1 | 2005 | 27 | 0.060 |
Why?
| | Autoantigens | 1 | 2008 | 396 | 0.060 |
Why?
| | Sensitivity and Specificity | 2 | 2009 | 1690 | 0.060 |
Why?
| | Histocompatibility Testing | 1 | 2004 | 115 | 0.060 |
Why?
| | Hyperglycemia | 1 | 2008 | 292 | 0.060 |
Why?
| | Antibodies, Heterophile | 1 | 2004 | 13 | 0.060 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 1 | 2004 | 44 | 0.060 |
Why?
| | Organ Specificity | 1 | 2005 | 266 | 0.060 |
Why?
| | Receptor-Like Protein Tyrosine Phosphatases, Class 8 | 1 | 2004 | 58 | 0.060 |
Why?
| | False Positive Reactions | 1 | 2004 | 109 | 0.060 |
Why?
| | Biological Evolution | 1 | 2008 | 406 | 0.060 |
Why?
| | Glutamate Decarboxylase | 1 | 2004 | 160 | 0.060 |
Why?
| | Single-Blind Method | 1 | 2004 | 259 | 0.060 |
Why?
| | HLA Antigens | 1 | 2005 | 220 | 0.050 |
Why?
| | Cohort Studies | 2 | 2022 | 4883 | 0.050 |
Why?
| | Protein Tyrosine Phosphatases | 1 | 2004 | 147 | 0.050 |
Why?
| | Immune Tolerance | 1 | 2005 | 321 | 0.050 |
Why?
| | Reproducibility of Results | 2 | 2007 | 2764 | 0.050 |
Why?
| | Clinical Trials as Topic | 1 | 2006 | 926 | 0.050 |
Why?
| | Karyotype | 1 | 2021 | 13 | 0.050 |
Why?
| | Chromosomes, Human, Y | 1 | 2021 | 13 | 0.050 |
Why?
| | Diabetes Mellitus | 1 | 2009 | 898 | 0.050 |
Why?
| | Genitalia | 1 | 2021 | 28 | 0.050 |
Why?
| | Algorithms | 1 | 2008 | 1469 | 0.040 |
Why?
| | Mosaicism | 1 | 2021 | 62 | 0.040 |
Why?
| | Liver Cirrhosis | 1 | 2022 | 227 | 0.040 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2021 | 308 | 0.040 |
Why?
| | Hypoglycemic Agents | 1 | 2007 | 1011 | 0.040 |
Why?
| | Young Adult | 2 | 2012 | 10444 | 0.040 |
Why?
| | Bone and Bones | 1 | 2002 | 277 | 0.040 |
Why?
| | Cross-Sectional Studies | 1 | 2009 | 4402 | 0.040 |
Why?
| | Prevalence | 1 | 2005 | 2247 | 0.040 |
Why?
| | Education, Medical, Graduate | 1 | 2022 | 366 | 0.040 |
Why?
| | Animals | 4 | 2008 | 31565 | 0.040 |
Why?
| | Proteins | 1 | 2004 | 906 | 0.040 |
Why?
| | Patient Compliance | 1 | 2002 | 524 | 0.040 |
Why?
| | Infant | 3 | 2006 | 7943 | 0.040 |
Why?
| | Phenotype | 2 | 2021 | 2784 | 0.040 |
Why?
| | Pedigree | 2 | 2010 | 460 | 0.040 |
Why?
| | Mice | 3 | 2008 | 14841 | 0.030 |
Why?
| | Prospective Studies | 2 | 2006 | 6195 | 0.030 |
Why?
| | Adult | 5 | 2011 | 30375 | 0.030 |
Why?
| | Reference Values | 2 | 2009 | 739 | 0.030 |
Why?
| | Parents | 1 | 2022 | 1181 | 0.030 |
Why?
| | Colorado | 1 | 2004 | 4090 | 0.030 |
Why?
| | Middle Aged | 3 | 2009 | 26605 | 0.020 |
Why?
| | HLA-B15 Antigen | 1 | 2011 | 13 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2022 | 4595 | 0.020 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 82 | 0.020 |
Why?
| | Rituximab | 1 | 2011 | 148 | 0.020 |
Why?
| | HLA-B8 Antigen | 1 | 2010 | 14 | 0.020 |
Why?
| | Syndrome | 1 | 2011 | 330 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2004 | 9049 | 0.020 |
Why?
| | Radioimmunoprecipitation Assay | 1 | 2009 | 6 | 0.020 |
Why?
| | Staphylococcal Protein A | 1 | 2009 | 9 | 0.020 |
Why?
| | Microchemistry | 1 | 2009 | 15 | 0.020 |
Why?
| | Linkage Disequilibrium | 1 | 2010 | 245 | 0.020 |
Why?
| | Immunologic Factors | 1 | 2011 | 217 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 2010 | 373 | 0.020 |
Why?
| | Nuclear Family | 1 | 2009 | 48 | 0.020 |
Why?
| | Europium | 1 | 2007 | 2 | 0.020 |
Why?
| | Luminescent Agents | 1 | 2007 | 7 | 0.020 |
Why?
| | Fluorometry | 1 | 2007 | 19 | 0.020 |
Why?
| | Risk | 1 | 2010 | 810 | 0.020 |
Why?
| | Metabolic Networks and Pathways | 1 | 2008 | 167 | 0.020 |
Why?
| | United States | 1 | 2022 | 12137 | 0.020 |
Why?
| | Aged | 1 | 2004 | 18969 | 0.020 |
Why?
| | Chromosomes, Human, Pair 6 | 1 | 2006 | 44 | 0.020 |
Why?
| | Mice, Inbred NOD | 1 | 2008 | 552 | 0.020 |
Why?
| | Family | 1 | 2009 | 589 | 0.020 |
Why?
| | Lung Diseases | 1 | 2011 | 690 | 0.020 |
Why?
| | Polyethylene Glycols | 1 | 2009 | 561 | 0.010 |
Why?
| | Family Health | 1 | 2005 | 193 | 0.010 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2009 | 1204 | 0.010 |
Why?
| | Survival Rate | 1 | 2006 | 1638 | 0.010 |
Why?
| | Chronic Disease | 1 | 2008 | 1577 | 0.010 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2004 | 787 | 0.010 |
Why?
|
|
Barker's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|